Hydrogen sulfide-based therapies: Focus on H2S releasing NSAIDs

Inflammation and Allergy - Drug Targets

Volumn 10, Issue 2, 2011, Pages 133-140

  Fiorucci, Stefano ^a   Santucci, Luca ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Azienda Ospedaliera Universitaria   (Italy)

Author keywords

Arthritis; Aspirin; CINODs; Coxibs; Cyclooxygeneases; Diclofenac; Hydrogen sulfide; Lipoxin; Naproxen; Nitric oxide; Non steroidal anti inflammatory drugs

Indexed keywords

2 (6 METHOXYNAPHTHALEN 2 YL)PROPIONIC ACID 4 THIOCARBAMOYLPHENYL ESTER; 2 [(2,6 DICHLOROPHENYL)AMINO]BENZENEACETIC ACID 4 (3H 1,2 DITHIOL 3 THION 5 YL)PHENYL ESTER; ACETYLSALICYLIC ACID DERIVATIVE; ACS 14; ACS 15; ACS 21; ACS 6; ATB 337; ATB 343; ATB 345; ATB 346; AZ 3582; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; DICLOFENAC DERIVATIVE; HYDROGEN SULFIDE; NAPROXCINOD; NAPROXEN; NAPROXEN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DIGESTIVE SYSTEM INJURY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HUMAN; NONHUMAN; THROMBOEMBOLISM;

EID: 79952747333     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152811794776213     Document Type: Article

References (55)

1. Pusztaszeri, M.P.; Genta, R.M.; Cryer, B.L. Drug-induced injury in the gastrointestinal tract: clinical and pathologic considerations. Nat. Clin. Pract. Gastroenterol. Hepatol., 2007, 4(8), 442-453.
2. Wolfe, M.M.; Lichtenstein, D.R.; Singh, G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med., 1999, 340(24), 1888-1899.
3. FitzGerald, G.A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov., 2003, 2(11), 879-890.
4. Fiorucci, S.; Distrutti, E.; Santucci, L. NSAIDs, Coxibs, CINOD and H2S-releasing NSAIDs, what lies beyond the horizon? Dig. Liver Dis., 2007, 39(12), 1043-1051.
5. Lana, S.A.; Perez-Aisa, M.A.; Feu, F.; Ponce, J.; Saperas, E.; Santolaria, S.; Rodrigo, L.; Balanzo, J.; Bajador, E.; Almela, P.; Navarro, J.M.; Carballo, F.; Castro, M.; Quintero, E.; Investigators of the Asociacion Espanola de Gastroenterologia (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug use. Am. J. Gastroenterol., 2005, 700(8),1685-1693.
6. Lanas, A.; Garcia-Rodriguez, L.A.; Arroyo, M.T.; Gomollon, F.; Feu, F.; Gonzalez-Perez, A.; Zapata, E.; Bastida, G.; Rodrigo, L.; Santolaria, S.; Giiell, M.; de Argila, C.M.; Quintero, E.; Borda, F.; Pique, J.M.; Asociacion Espanola de Gastroenterologia. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut., 2006, 55(12), 1731-1738.
7. Silverstein, E.; Graham, D.Y.; Senior, J.R.; Davies, H.W.; Struthers B.J.; Bittman, R.M.; Geis, G.S. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med., 1995, 723(4), 241-249.
8. Hawkey, C.J.; Karrasch, J.A.; Szczepanski, L.; Walker, D.G.; Barkun, A.; Swannell, A.J.; Yeomans, N.D. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group, N. Engl. J. Med.,1998, 338(11), 727-734.
9. Chan. F.K.L. The role of proton pump inhibitors in the management of upper gastrointestinal bleeding. Gastroenterol. Clin. North Am., 2009, 38,199-214.
10. Fiorucci, S. Prevention of nonsteroidal anti-inflammatory drug induced ulcers: looking to the future. Gastroenterol. Clin. North Am., 2009, 38(2), 315-322.
11. Wallace, J.L.; Ignarro, L.J.; Fiorucci, S. Potential cardioprotective actions of nitric oxide-releasing aspirin. Nature Rev. Drug Discov., 2002, 7(5), 375-382.
12. Murad, F. Nitric oxide and cyclic GMP in cell signaling and drug development. N. Engl. J. Med., 2006, 355(19), 2003-2011.
13. Wang, R. Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter? FASEB J., 2002, 76(13), 1792-1798.
14. Szabo, C. Hydrogen sulfide and its therapeutic potential. Nat. Rev. Drug Discovery, 2007, 6(11), 917-935.
15. Fiorucci, S.; Distrutti, E.; Cirino, G.; Wallace, J. L. The emerging roles of hydrogen sulfide in the gastrontestinal tract and liver. Gastroenterology, 2006, 737(1), 259-272.
16. Fallace, J.L.; Keenan, C.M.; Granger, D.N. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil- dependent process. Am. J. Physiol., 1990, 259(3 Pt1), G462-G467.
17. Santucci, L.; Fiorucci, S.; Di Matteo, F.M.; Morelli, A. Role of tumor necrosis factor alpha release and leukocyte margination in indomethacin-induced gastric injury in rats. Gastroenterology, 1995, 708(2), 393-401.
18. Whittle, B.J.; Lopez-Belmonte, J.; Moncada, S. Nitric oxide mediates rat mucosal vasodilatation induced by intragastric capsaicin. Eur. J. Pharmacol., 1992, 278(2-3), 339-41.
19. Wallace, J.L.; Reuter, B.; Cicala, C.; McKnight, W.; Grisham, M.B.; Cirino, G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology, 1994, 707(1), 173-179.
20. Anonymous. Nitronaproxen: AZD 3582, HCT 3012, Naproxen Nitroxybutylester, NO-Naproxen. Drugs R. D., 2006, 7(4), 262-266.
21. Wallace, J.L.; Caliendo, G.; Santagada, V.; Cirino, G.; Fiorucci, S. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulphide-releasing diclofenac derivative in the rat. Gastroenterology, 2007, 732(1), 261-271.
22. Li, L.; Rossoni, G.; Sparatore, A.; Lee, L.C.; Del Soldato, P.; Moore, P.K. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic. Biol. Med., 2007, 42(5), 706-719.
23. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M.B.; Hawkey, C.J.; Hochberg, M.C.; Kvien, T.K.; Schnitzer, T.J.; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 2000, 343(21), 1520-1528.
24. Silverstein, F.E.; Faich, G.; Goldstein, J.L.; Simon, L.S.; Pincus, T.; Whelton, A, Makuch, R.; Eisen, G.; Agrawal, N.M.; Stenson, W.F.; Burr, A.M.; Zhao, W.W.; Kent, J.D.; Lefkowith, J.B.; Verburg, K.M.; Geis, G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000, 284(10), 1247-1255.
25. Schnitzer, T.J.; Burmester, G.R.; Mysler, E.; Hochberg, M.C.; Doherty, M.; Ehrsam, E.; Gitton, X.; Krammer, G.; Mellein, B.; Matchaba, P.; Gimona, A.; Hawkey, C.J.; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet, 2004, 364(9435), 665-674.
26. Farkouh, M.E.; Kirshner, H.; Harrington, R.A.; Ruland, S.; Verheugt, F.W.; Schnitzer, T.J.; Burmester, G.R.; Mysler, E.; Hochberg, M.C.; Doherty, M. Ehrsam, E.; Gitton, X.; Krammer, G.; Mellein, B.; Gimona, A.; Matchaba, P.; Hawkey, C.J.; Chesebro, J.H.; TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet, 2004, 364(9435), 675-684.
27. Nussmeier, N.A.; Whelton, A.A.; Brown, M.T.; Langford, R.M.; Hoeft, A.; Parlow, J.L.; Boyce, S.W.; Verburg, K.M. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med., 2005, 352(11), 1081-1091.
28. Johnsen, S.P.; Larsson, H.; Tarone, R.E.; McLaughlin, J.K.; Norgard, B.; Friis, S.; Sorensen, H.T. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch. Intern. Med., 2005, 765(9), 978-984.
29. Juni, P.; Nartey, L.; Reichenbach, S.; Sterchi, R.; Dieppe, P.A.; Egger, M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet, 2004, 364(9450), 2021-2029.
30. Bresalier, R.S.; Sandler, R.S.; Quan, H.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M.A.; Baron, J.A.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med., 2005, 352(11), 1092-1102.
31. Fiorucci, S.; Santucci, L.; Wallace, J.L.; Sardina, M.; Romano, M.; del Soldato, P.; Morelli, A. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc. Natl. Acad. Sci. USA, 2003, 700(19), 10937-10941.
32. Fiorucci, S.; Distrutti, E.; de Lima, O.M.; Romano, M.; Mencarelli, A.; Barbanti, M.; Palazzini, E.; Morelli, A.; Wallace, J.L. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J., 2003, 7 7(9), 1171-1173.
33. Fiorucci, S.; de Lima, O.M. Jr.; Mencarelli, A.; Palazzotti, B.; Distrutti, E.; McKnight, W.; Dicay, M.; Ma, L.; Romano, M.; Morelli, A.; Wallace, J.L. Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology, 2002, 723(5), 1598-1606.
34. Hawkey, C.; Jones, J.I.; Atherton, C.T.; Skelly, M.M.; Bebb, J.R.; Fagerholm, U.; Jonzon, B.; Karlsson, P.; Bjarnason, I.T. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut, 2003, 52(11), 1537-1542.
35. Lohmander, L.S.; McKeith, D.; Svensson, O.; Malmenas, M.; Bolin, L.; Kalla, A.; Genti, G.; Szechinski, J.; Ramos-Remus, C.; STAR Multinational Study Group. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann. Rheum. Dis., 2005, 64(3), 449-456.
36. Fiorucci, S.; Antonelli, E. NO-NSAIDs: from inflammatory mediators to clinical readouts. Inflamm. Allergy Drug Targets, 2006, 5(2), 121-131.
37. Fiorucci, S.; Antonelli, E.; Distrutti, E.; Rizzo, G.; Mencarelli, A.; Orlandi, S.; Zanardo, R.; Renga, B.; Di Sante, M.; Morelli, A.; Cirino, G.; Wallace, J. L. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology, 2005, 729(4), 1210-1224.
38. Wallace, J.L.; Caliendo, G.; Santagada, V.; Cirino, G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br. J. Pharmacol., 2010, 759(6), 1236-1246.
39. Zanardo, R. C.; Brancaleone, V.; Distrutti, E.; Fiorucci, S.; Cirino, G.; Wallace, J. L. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J., 2006, 20(12), 2118-2120.
40. Sparatore, A.; Perrino, E.; Tazzari, V.; Giustarini, D.; Rossi, R.; Rossoni, G.; Erdmann, K.; Schroder, H.; Del Soldato, P. Pharmacological profile of a novel H(2)S-releasing aspirin. Free Radic. Biol. Med., 2009, 46(5), 586-592.
41. Lee, M.; Sparatore, A.; Del Soldato, P.; McGeer, E.; McGeer, PL. Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia, 2010, 58(1), 103-113.
42. Moody, T.W.; Switzer, C.; Santana-Flores, W.; Ridnour, L.A.; Berna, M.; Thill, M.; Jensen, R.T.; Sparatore, A.; Del Soldato, P.; Yeh, G.C.; Roberts, D.D.; Giaccone, G.; Wink, D.A. Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. Lung Cancer, 2010, 68(2), 154-160.
43. Giustarini, D.; Del Soldato, P.; Sparatore, A.; Rossi, R. Modulation of thiol homeostasis induced by H2S-releasing aspirin. Free Radic. Biol. Med., 2010, 48(9), 1263-1272.
44. Isenberg, J.S.; Jia, Y.; Field, L.; Ridnour, L.A.; Sparatore, A.; Del Soldato, P.; Sowers, A.L.; Yeh, G.C.; Moody, T.W. D.A.; Ramchandran, R.; Roberts, D.D. Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br. J. Pharmacol., 2007, 757(1), 63-72.
45. Sidhapuriwala, J.; Li, L.; Sparatore, A.; Bhatia, M.; Moore, P.K. Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative, on carrageenan-induced hindpaw oedema formation in the rat. Eur. J. Pharmacol., 2007, 569(1-2), 149-154
46. Bhatia, M.; Sidhapuriwala, J.N.; Sparatore, A.; Moore, P.K. Treatment with H2S-releasing diclofenac protects mice against acute pancreatitis-associated lung injury. Shock, 2008, 29(1), 8488.
47. Rossoni, G.; Sparatore, A.; Tazzari, V.; Manfredi, B.; Del Soldato, P.; Berti, F. The hydrogen sulphide-releasing derivative of diclofenac protects against ischaemia-reperfusion injury in the isolated rabbit heart. Br. J. Pharmacol., 2008, 753(1), 100-109.
48. Baskar, R.; Sparatore, A.; Del Soldato, P.; Moore, P.K. Effect of S- diclofenac, a novel hydrogen sulfide releasing derivative inhibit rat vascular smooth muscle cell proliferation. Eur. J. Pharmacol., 2008, 594(1-3), 1-8.
49. Bass, S.; Sienkiewicz, P.; Macdonald, C.J.; Cheng, R.Y.; Sparatore, A.; Del Soldato, P.; Roberts, D.D.; Moody, T.W.; Wink, D.A.; Yeh, G.C. Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells. Clin. Cancer Res., 2009, 75(6), 1964-1972.
50. Lee, M.; Sparatore, A.; Del Soldato, P.; McGeer, E.; McGeer, P.L. Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia, 2010, 58(1), 103-113.
51. Sparatore, A.; Perrino, E.; Tazzari, V.; Giustarini, D.; Rossi, R.; Rossoni, G.; Erdmann, K.; Schroder, H.; Del Soldato, P. Pharmacological profile of a novel H(2)S-releasing aspirin. Free Radic. Biol. Med., 2009, 46(5), 586-592.
52. Giustarini, D.; Del Soldato, P.; Sparatore, A.; Rossi, R. Modulation of thiol homeostasis induced by H2S-releasing aspirin. Free Radic. Biol. Med., 2010, 48(9), 1263-1272.
53. Wallace, J. L.; Vong, L. NSAID-induced gastrointestinal damage and the design of Gl-sparing NSAIDs. Curr. Opin. Invest. Drugs, 2008, 9(11), 1151-1156.
54. Wallace, J. L. Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol. Sci., 2007, 28(10), 501- 550.
55. Bucci, M.; Cirino, C. Hydrogen sulphide in heart and systemic circulation. Inflam. Allergy Drug Targets, 2011, 70(2), 103-108.